BCLI

Brainstorm Cell Therapeutics Inc
1.82
0.00 (0.00%)

Brainstorm Cell Therapeutics Inc. (BCLI) Fundamentals

Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
SHARE INFORMATION
Market Cap$ 66,506,038
Shares Outstanding36,541,779
Float33,704,002
Percent Float92.23%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 0
Latest Fiscal EPS$ -0.68
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions83
Institutional Holdings Date2022-12-31
Institutional Bought Previous 3 Months189,352
Institutional Holdings Percent22.0%
Institutional Sold Previous 3 Months109,146
Insider Holdings Date2022-12-31
Insider Bought Previous 3 Months-
Insider Holdings Percent6.6
Insider Sold Previous 3 Months-
Insider Shares Owned2,419,481
TRADING INFO
52 Week High$ 4.70
52 Week Low$ 1.09
52 Week High Change$ -41.67
21 Day Moving Average$ 1.5664
21 Day Extended Moving Average$ 1.5914
50 Day Moving Average$ 1.6151
50 Day Extended Moving Average$ 1.8111
200 Day Moving Average$ 2.7878
200 Day Extended Moving Average$ 2.6558
10 Day Average Volume147,917
20 Day Average Volume230,826
30 Day Average Volume219,697
50 Day Average Volume201,506
Alpha0.014357
Beta-0.4284
Standard Deviation0.227737
R20.010288
7 Day Price Change$ 0.37
7 Day Percent Change25.52%
21 Day Price Change$ 0.21
21 Day Percent Change13.04%
30 Day Price Change$ 0.18
30 Day Percent Change10.98%
Month to Date Price Change$ 0.18
Month to Date Percent Change10.98%
Quarter to Date Price Change$ 0.18
Quarter to Date Percent Change10.98%
180 Day Price Change$ -0.74
180 Day Percent Change-28.91%
200 Day Price Change$ -0.82
200 Day Percent Change-31.06%
Year to Date Price Change$ 0.18
Year to Date Percent Change10.98%

Brainstorm Cell Therapeutics Inc. (BCLI) Key Ratios

PROFITABILITY
EBIT Margin0.0%
EBITDA Margin0.0%
Pre-Tax Profit Margin0.0%
Profit Margin Count0.0%
Gross Margin0.0%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 0
Revenue Per Share$ 0.00
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book45.90
Total Debt To Equity3.20
Int Coverage0.00
Current Ratio0.80
Leverage Ratio2.50
Quick Ratio0.80
Long Term Debt To Capital0.68
VALUATION MEASURES
PE Ratio-2.50
Enterprise Value$ 60,750,404
Price to Sales0.00
Price to Free Cash-4.30
PE High Last 5 Years-6.40
Price To Book45.90
Price To Cash Flow0.00
PE Low Last 5 Years-10.70
Price to Tangible Book45.90
MANAGEMENT EFFECTIVENESS
Receivables Turnover0.00
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-119.72
Return on Equity-226.18
Return on Capital-140.63

Brainstorm Cell Therapeutics Inc. (BCLI) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorBrightman Almagor Zohar & Co.
CEOStacy R. Lindborg / Chaim Lebovits
Emplyoees43
Last AuditUQ
CIK0001137883
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address1325 Avenue of Americas
28th Floor
New York, NY 10019
Websitehttps://www.brainstorm-cell.com
Facsimile+1 201 430-7555
Telephone+1 201 488-0460
Emailpshah@brainstorm-cell.com


Your Recent History
NASDAQ
BCLI
Brainstorm..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.